Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | PPARA | Q07869 | 1/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.55 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL415441 | 0.89 | FFAR1 (0.68) | FFAR1PTGDR2SRD5A2NR3C1FFAR4 | |
| SCHEMBL4433185 | 0.88 | PTGDR2 (0.51) | PPARGPPARAFFAR1DAGLAPTGDR2 | |
| SCHEMBL14280737 | 0.88 | FFAR1 (0.53) | PPARGPPARAFFAR1DAGLAPTGDR2 | |
| Hydrochloric Acid SCHEMBL8694026 | 0.87 | FFAR1 (0.67) | FFAR1PTGDR2SRD5A2NR3C1FFAR4 | |
| SCHEMBL9262220 | 0.86 | PPARG (0.56) | PPARGPPARADAGLAP2RX3LMNA | |
| Methane SCHEMBL27637860 | 0.85 | FFAR1 (0.65) | FFAR1PTGDR2SRD5A2NR3C1FFAR4 | |
| SCHEMBL12440458 | 0.84 | P2RX3 (0.58) | PPARGPPARADAGLAP2RX3LMNA | |
| SCHEMBL4440017 | 0.84 | PTGDR2 (0.52) | PPARGPPARAFFAR1PTGDR2FFAR4 | |
| SCHEMBL6441891 | 0.83 | SRD5A2 (0.62) | PPARGPPARAFFAR1DAGLAPTGDR2 | |
| SCHEMBL7911502 | 0.83 | FFAR1 (0.59) | FFAR1SRD5A2NR3C1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177055-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-07-21 | — | — | US | disclosed |
| US-20110177055-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-07-21 | — | — | US | disclosed |
| US-20110177055-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-07-21 | — | — | US | disclosed |
| US-7939547-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-10 | — | — | US | disclosed |
| US-7939547-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-10 | — | — | US | disclosed |
| US-7939547-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-10 | — | — | US | disclosed |
| EP-2019837-B1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-03-23 | — | — | EP | disclosed |
| EP-2019837-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007140117-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2007-12-06 | — | — | WO | disclosed |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| EP-0595995-B1 | ARYLAMIDOALKYL- AND ARYLAMINOALKYL-N-HYDROXYUREA COMPOUNDS AND -N-HYDROXYFORMAMIDE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 1997-01-15 | — | — | EP | disclosed |
| US-5514702-A | Arylamidoalkyl-N-hydroxyurea compounds having lipoxygenase inhibitory activity | ABBOTT LABORATORIES (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0595995-A4 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0595995-A1 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY. | ABBOTT LAB (US) | 1994-05-11 | — | — | EP | disclosed |
| WO-1993002037-A1 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LABORATORIES (US) | 1993-02-04 | — | — | WO | disclosed |
| US-3985779-A | ANTIINFLAMMATORY AND ANALGESIC ACTIVITIES | EISAI CO., LTD. (JA) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | PPARG 3950/4885PPARA 4171/4885FFAR1 3121/4885 |
| US-20110177055-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | PPARG 3960/4885PPARA 4175/4885FFAR1 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.